Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2/3 BFAST trial.
Peters S, Gadgeel SM, Mok T, Nadal E, Kilickap S, Swalduz A, Cadranel J, Sugawara S, Chiu CH, Yu CJ, Moskovitz M, Tanaka T, Nersesian R, Shagan SM, Maclennan M, Mathisen M, Bhagawati-Prasad V, Diarra C, Assaf ZJ, Archer V, Dziadziuszko R.
Peters S, et al. Among authors: tanaka t.
Nat Med. 2024 Jun 19. doi: 10.1038/s41591-024-03008-4. Online ahead of print.
Nat Med. 2024.
PMID: 38898120